These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Therapy of psoriasis 1975. Van Scott EJ JAMA; 1976 Jan; 235(2):197-8. PubMed ID: 946030 [No Abstract] [Full Text] [Related]
27. [Immunosuppressive agents in the treatment of psoriasis]. Ruszczak Z Vestn Dermatol Venerol; 1976 Jan; (1):35-40. PubMed ID: 997862 [No Abstract] [Full Text] [Related]
28. An appraisal of current systemic chemotherapy for psoriasis. Farber EM; Pearlman D; Abel EA Arch Dermatol; 1976 Nov; 112 Spec no():1679-88. PubMed ID: 793537 [No Abstract] [Full Text] [Related]
29. Time-response curves in the evaluation of the clinical efficacy of drugs. Jankú I; Elis J; Rasková H Eur J Clin Pharmacol; 1971 Sep; 3(4):194-7. PubMed ID: 5151302 [No Abstract] [Full Text] [Related]
30. Nucleoside analogs in the treatment of nonneoplastic diseases. Calabresi P; Doolittle CH; Heppner GH; McDonald CJ Ann N Y Acad Sci; 1975 Aug; 255():190-201. PubMed ID: 1059354 [No Abstract] [Full Text] [Related]
31. Abortifacient and teratogenic effects of triacetyl-6-azauridine in the monkey. van Wagenen G; DeConti RC; Handschumacher RE; Wade ME Am J Obstet Gynecol; 1970 Sep; 108(2):272-81. PubMed ID: 4952580 [No Abstract] [Full Text] [Related]
32. Cutaneous uses of the antiproliferative drugs. McDonald CJ Clin Pharmacol Ther; 1974 Nov; 16(5 Part 2):934-9. PubMed ID: 4138632 [No Abstract] [Full Text] [Related]
33. Changes in preference for NaCl following administration of 6-azauridine and 6-azauridine triacetate. Catalanotto FA; Slavik M; Danilson D; Keiser HR; Henkin RI Pharmacol Ther Dent; 1975; 2(1):25-32. PubMed ID: 1054856 [TBL] [Abstract][Full Text] [Related]
34. The thrombogenicity of 6-azouridine. Gitel SN; Grieco AJ; Wessler S; Snyderman SE Haemostasis; 1979; 8(1):54-7. PubMed ID: 456945 [TBL] [Abstract][Full Text] [Related]
35. Postmarketing surveillance of new drugs: II. Case studies. Wardell WM; Tsianco MC; Anavekar SN; Davis HT J Clin Pharmacol; 1979 Apr; 19(4):169-84. PubMed ID: 374427 [No Abstract] [Full Text] [Related]
36. Changes in amino acid metabolism caused by 6-azauridine triacetate: relevance to cancer treatment. Slavik M Cancer Treat Rep; 1979 Jun; 63(6):1041-4. PubMed ID: 582429 [TBL] [Abstract][Full Text] [Related]
38. Decrease of serum pyridoxal phosphate levels and homocystinemia after administration of 6-azauridine triacetate and their prevention by administration of pyridoxine. Slavik M; Smith KJ; Blanc O Biochem Pharmacol; 1982 Dec; 31(24):4089-92. PubMed ID: 6186258 [No Abstract] [Full Text] [Related]
39. Combination chemotherapy with cytosine arabinoside, L-asparaginase, and 6-azauridine for transplantable murine leukemias. Avery TL; Roberts D Cancer Res; 1973 Apr; 33(4):791-9. PubMed ID: 4696479 [No Abstract] [Full Text] [Related]
40. Change in shape and location of non-vascularized area of ventricular myocardium in chick embryo during terminal phase of heart vascularization after administration of 6-azauridine in different doses. Rychter Z; Jelínek R Folia Morphol (Praha); 1973; 21(1):1-11. PubMed ID: 4734537 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]